Teti G
Ann Sclavo. 1980 Jan-Feb;22(1):34-9.
Influenza mortality and morbidity underscore the need for a more immunogenic influenza vaccine with a shorter production time. Techniques of rapid derivation of mutants and of genetic recombination appear promising in producing vaccines, responsive to major antigenic shifts of influenza virus. "Cold" adapted, inhibitor resistant and temperature sensitive mutants have all proven safe and effective in adults as live influenza vaccines. The property of attenuation for man can be transferred in many instances from well adapted laboratory strains to new variants of wild viruses by genetic recombination. This technique will be useful in the continual updating of live influenza vaccines.
流感的死亡率和发病率凸显了研发一种生产时间更短、免疫原性更强的流感疫苗的必要性。快速获得突变体和基因重组技术在生产能应对流感病毒主要抗原转变的疫苗方面似乎很有前景。“冷适应”、抑制剂抗性和温度敏感的突变体作为活流感疫苗在成年人中已被证明是安全有效的。在许多情况下,通过基因重组,可将对人类的减毒特性从适应良好的实验室毒株转移到野生病毒的新变种上。这项技术将有助于活流感疫苗的持续更新。